Neuralink Stock: How to Invest Before the IPO
You can’t buy Neuralink on the stock market. You can, however, buy shares in companies that supply parts of the science and technology behind brain-computer interfaces. That distinction matters: the supply chain offers ways to invest in the theme, but it doesn’t make these stocks proxies for Neuralink.
Neuralink draws attention partly because Elon Musk is behind it and partly because reports have put its valuation at $42 billion amid IPO speculation. But the company remains private, with no public ticker and no announced IPO date. For most investors, the practical question is where else the field is developing—and what risks come with those alternatives.
Brain-computer interface, or BCI, companies work on technology that connects brain signals with machines. That can include implants, imaging systems, sequencing tools, chips and other equipment. Neuralink is the best-known name in the conversation, but it isn’t the only company involved—and it’s not publicly investable.
Where public investors can get exposure
I outlined this group of companies in April 2026, before the Neuralink IPO discussion grew louder. The idea is that investors can follow parts of the BCI supply chain through public companies working on sequencing, imaging, chips and implants.
There are reasons the field is drawing attention: large companies are investing in it, the first U.S. pivotal trial for an implanted interface is underway, and regulators are clearing faster paths to market. Brain mapping is also becoming a sequencing problem. Still, those developments don’t establish which public suppliers will benefit most, or when. The connection between a company’s products and future BCI demand can be indirect.
BCI stocks to watch
Quantum-Si (QSI) is my favorite protein-sequencing play on the idea that sequencing will matter more in this field. It’s a volatile micro-cap that has surged on recent news and trading volume. Disclosure: I’m personally long QSI and treat it like a call option, sized small.
Butterfly Network (BFLY) makes ultrasound-on-a-chip devices, is further along commercially and reports earnings in late October.
Hyperfine (HYPR) is a micro-cap focused on portable MRI. Nautilus Biotechnology (NAUT) works in proteomics and has moved alongside other stocks in the group.
Medtronic (MDT) offers a more established medtech business. Investors looking for exposure through larger suppliers can also consider companies providing computing, memory and scientific instruments: Nvidia (NVDA), Broadcom (AVGO) and Micron (MU) supply compute and memory, while Thermo Fisher (TMO) and Bruker (BRKR) make instruments and microscopes.
Keep the risks in view
Many of the smaller names are micro-caps, and their shares can swing on news and momentum. Size speculative positions so that a total loss wouldn’t damage your finances; with a micro-cap, that outcome is possible. Catalysts such as earnings, FDA filings and early approval steps can move prices, while stocks tied to the same theme may rise and fall together. A small basket can reduce dependence on a single company, but it won’t remove the risk of a broad selloff.
Neuralink remains private as of 2026, and it has not announced an IPO date. Any proposed timeline is speculation. Public BCI-related companies include firms working on implants, imaging and sequencing, among them QSI, BFLY, HYPR and MDT.
You don’t need Neuralink shares to invest in companies connected to the BCI field. But the supply-chain angle is not a shortcut to owning Neuralink, and the smaller stocks can be especially risky. Know what each company does, size speculative positions accordingly, and pay attention to the catalysts that may affect them.
This article is for educational purposes only and is not investment advice. Do your own research before investing.
Jonathan Rose has spent decades as a professional trader. Masters in Trading LIVE is his free class, held for 15 minutes every market morning at 11 a.m. ET, where he discusses the setups and sectors he’s watching. Sign up for free here.
About the analyst
Jonathan Rose, editor of Masters in Trading: Daily Live, has spent more than two decades trading and teaching. He started on the floor of the Chicago Mercantile Exchange in 1997, managing Nasdaq and S&P 500 futures during the dot-com boom. That background gives him a long view of fast-moving markets—useful context for readers weighing the risks around a prospective IPO.